LIVN - LivaNova PLC
Bank of America Corp DE cut its holdings in shares of LivaNova PLC (NASDAQ: LIVN) by 30.6% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 533,017 shares of the company's stock after selling 235,233 shares during the quarter. Bank of America Corp
LivaNova (NASDAQ: LIVN - Get Free Report) and Dynatronics (NASDAQ: DYNT - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk. Risk and Volatility LivaNova has a beta of 0.86, indicating
LIVN's Q2 earnings and revenues beat estimates as Cardiopulmonary and Epilepsy growth fuels margin gains and a raised 2026 outlook.
LivaNova PLC (LIVN) Q2 2026 Earnings Call Transcript
LivaNova NASDAQ: LIVN reported record quarterly revenue and adjusted earnings per share for the second quarter of 2026, citing double-digit reported growth across its Cardiopulmonary and Epilepsy businesses. The company raised its full-year revenue and adjusted EPS outlook while reducing its adjusted free-cash-flow forecast to account for increased investment in manufacturing capacity, innovation and IT infrastructure.
While the top- and bottom-line numbers for LivaNova (LIVN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
LivaNova (LIVN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
LivaNova (LIVN) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $1.08 per share. This compares to earnings of $1.05 per share a year ago.
GLOUCESTER, England--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the second quarter ended June 30, 2026 and raised full-year 2026 guidance. Financial Summary and Highlights(1) Second-quarter revenue of $390.6 million increased 10.8% on a reported basis and 9.8% on a constant-currency basis as compared to the prior-year period Second-quarter U.S. GAAP diluted earnings per share of $1.93 and adjusted diluted earnings per sh.
Amundi cut its position in shares of LivaNova PLC (NASDAQ: LIVN) by 3.5% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 172,784 shares of the company's stock after selling 6,304 shares during the quarter. Amundi owned approximately 0.31% of LivaNova worth
Bank of New York Mellon Corp lessened its holdings in shares of LivaNova PLC (NASDAQ: LIVN) by 34.3% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 394,391 shares of the company's stock after selling 206,050 shares during the period. Bank
GenAI creates new opportunities for ISRG, ALC and LIVN, even as regulatory, inflation and industry headwinds continue to pressure MedTech.
LivaNova (LIVN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2026 results on Wed., Aug. 5, 2026, at 1 p.m. London time (8 a.m. Eastern Daylight Time). The Company will release its second-quarter 2026 results prior to the call. The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To lis.
LIVN's PolySync data show an 84.5% AHI response rate in OSA patients, building on OSPREY results for its aura6000 System.
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced new data showing that use of its PolySync™ programming algorithm increased the cumulative apnea-hypopnea index (AHI) response rate to 84.5% in patients with moderate to severe Obstructive Sleep Apnea (OSA) when treated with proximal hypoglossal nerve stimulation (pHGNS). The findings were presented at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societie.
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced the election of Jette Nygaard-Andersen to the Company's Board of Directors after its Annual General Meeting of shareholders on June 10. “We're pleased to welcome Jette to LivaNova's Board,” said William Kozy, Chair. “She brings deep medtech governance expertise, proven CEO leadership, and a strong track record of transformation, strategic M&A, and digital innovation across complex gl.
LivaNova PLC (LIVN) Shareholder/Analyst Call Prepared Remarks Transcript
LivaNova PLC (LIVN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the appointment of Anne Liddy as Chief Legal Officer, effective Augus